Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580342 | 1.00 | MAPK1 (0.41) | MAPK1P2RX7BRD4CHRM2CHRM1 | |
| SCHEMBL2575412 | 0.77 | P2RX7 (0.39) | MAPK1P2RX7BRD4POLBGAA | |
| SCHEMBL2575409 | 0.77 | P2RX7 (0.39) | MAPK1P2RX7BRD4POLBGAA | |
| SCHEMBL23230738 | 0.70 | P2RX7 (0.40) | MAPK1P2RX7CHRM2CHRM1CHRM3 | |
| SCHEMBL24750243 | 0.70 | P2RX7 (0.40) | MAPK1P2RX7CHRM2CHRM1CHRM3 | |
| SCHEMBL13401215 | 0.70 | BRD4 (0.38) | MAPK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL21533414 | 0.68 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL25190428 | 0.67 | MAPT (0.40) | CHRM2CHRM1CHRM3NFKB1NFKB2 | |
| SCHEMBL10110525 | 0.67 | POLB (0.32) | POLB | |
| SCHEMBL14231590 | 0.67 | POLB (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | MAPK1 1398/4885P2RX7 1/4885BRD4 4135/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | MAPK1 1398/4885P2RX7 1/4885BRD4 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.